Will current market headwinds cause the IPO window to close?
By Peter Winter
Monday, April 21, 2014
It will come as no surprise that the Street's passion for biotech initial public offerings (IPO) has waned lately in the wake of the sector's overall poor market performance during the past few weeks.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.